XETR
NN6
Market cap24mUSD
Oct 09, Last price
1.73EUR
1D
-0.57%
1Q
-19.53%
Jan 2017
87.82%
IPO
-5.46%
Name
NanoRepro AG
Chart & performance
P/E
—
P/S
4.69
EPS
—
Div yield, %
—
Shrs. gr., 5y
6.21%
Rev. gr., 5y
-22.76%
Revenues
5m
+0.14%
Net income
-2m
CFO
0
-100.00%
Dividend
Jun 16, 20230.15 EUR/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Based in Marburg, Germany, NanoRepro AG specializes in the development, manufacturing, and international distribution of both swift diagnostic tests and nutritional supplements, serving individual consumers and healthcare professionals alike. Their diagnostic offerings encompass family planning, various disease detection, identification of food intolerances, allergies, and infectious diseases. This portfolio includes dedicated rapid test lines for allergies, family planning, and preventive healthcare. For hospitals and medical practices, they provide point-of-care tests capable of detecting conditions such as HIV, human cardiac Troponin I, D-dimer, streptococci antigens, influenza types A and B, and microalbumin. The company also produces immunochromatographic lateral flow tests for biomarker identification, alongside rapid SARS-CoV-2 antibody and antigen tests. Complementing their diagnostics, NanoRepro AG offers food supplements tailored for men and women, distributed via online stores and pharmacies.
Key people
Lisa Juengst
Chief Executive Officer
Michael Fuchs
Chief Financial Officer · since 2016
Chairman of the Supervisory Board · since 2013
Michael J. Tillman
Vice Chairman of the Supervisory Board
Bhuwnesh Agrawal
Member of the Supervisory Board
Clemens Jakopitsch
Member of the Supervisory Board
Member of the Supervisory Board
Headquarters & legal address
Untergasse 8
Marburg, HE 35037
DE
Marburg, HE 35037
DE
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||